Translational Drug Development (TD2)
Chelsea Holmquist is a seasoned project manager at Translational Drug Development (TD2), overseeing scientific staff and collaborating on preclinical studies since June 2013. Previous roles include Data Specialist at TD2, where all aspects of preclinical data reporting and analysis were managed, and Assistant Laboratory Manager at Celebration Stem Cell Centre, coordinating cord blood processing operations. Experience also includes a Research Technician position at COVANCE LABORATORIES LIMITED, focused on in-vivo preclinical toxicity studies, and a Research Associate role at Capstone Therapeutics, conducting preclinical research on drug mechanisms. Chelsea's academic qualifications include a Bachelor of Science in Molecular Bioscience and Biotechnology from Arizona State University and a Master's degree in Biotechnology, currently pursued at The Johns Hopkins University.
This person is not in the org chart
This person is not in any teams
Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.